Investing.com - Financial Markets Worldwide

ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)

Hong Kong
Currency in HKD
11.06
+0.05(+0.45%)
Closed·
1541 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
1541 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
10.7011.35
52 wk Range
3.2115.66
Key Statistics
Edit
Bid/Ask
11.06 / 10.93
Prev. Close
11.06
Open
11.01
Day's Range
10.7-11.35
52 wk Range
3.21-15.66
Volume
1.17M
Average Volume (3m)
4.77M
1-Year Change
4.93%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1541 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
21.84
Upside
+97.49%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 12
Analysts anticipate sales growth in the current year
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

ImmuneOnco Biopharmaceuticals Shanghai Inc Company Profile

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in the People’s Republic of China. The company’s core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination with azacitidine for the first-line treatment of higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia; and Phase III clinical trial in combination with tislelizumab, targeting relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) patients who relapsed or progressed after the treatment of PD-1 inhibitors. It also develops IMM0306 that is in Phase Ib/IIa clinical trial for the treatment of R/R CD20-positive B-cell non-Hodgkin lymphoma (B-NHL); IMM2510, which is in Phase Ib/IIa clinical trial to treat R/R soft tissue sarcoma; IMM27M that in Phase I clinical trial to treat solid tumors; IMM2520, which is in Phase I clinical trial for solid tumors; and IMM47 for the treatment of advanced malignant and solid tumors, and R/R B-NHL. In addition, the company develops IMC-002 for treating autoimmune indications; IMC-001 for the treatment of atherosclerosis; IMM72; IMM7211b; IMM51, IMM38, IMM50, and IMM62 for solid tumors; and IMM40H for liquid/solid tumors. It has license and collaboration agreement with Instil Bio, Inc. for the development of IMM2510 and IMM27M. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. was incorporated in 2015 and is headquartered in Shanghai, China.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
156
Market
Hong Kong

Compare 1541 to Peers and Sector

Metrics to compare
1541
Peers
Sector
Relationship
P/E Ratio
−13.1x−11.0x−0.5x
PEG Ratio
−0.650.060.00
Price/Book
6.1x5.4x2.6x
Price / LTM Sales
51.8x16.0x3.3x
Upside (Analyst Target)
97.5%26.1%43.4%
Fair Value Upside
Unlock−5.8%7.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.84
(+97.49% Upside)

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
-0.39 / --
Revenue / Forecast
78.82M / --
EPS Revisions
a
a
Unlock
Last 90 days

1541 Income Statement

FAQ

What Stock Exchange Does ImmuneOnco Biopharmaceuticals Trade On?

ImmuneOnco Biopharmaceuticals is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for ImmuneOnco Biopharmaceuticals?

The stock symbol for ImmuneOnco Biopharmaceuticals is "1541."

What Is the ImmuneOnco Biopharmaceuticals Market Cap?

As of today, ImmuneOnco Biopharmaceuticals market cap is 4.50B.

What Is ImmuneOnco Biopharmaceuticals's Earnings Per Share (TTM)?

The ImmuneOnco Biopharmaceuticals EPS (TTM) is -0.84.

From a Technical Analysis Perspective, Is 1541 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has ImmuneOnco Biopharmaceuticals Stock Split?

ImmuneOnco Biopharmaceuticals has split 0 times.

How Many Employees Does ImmuneOnco Biopharmaceuticals Have?

ImmuneOnco Biopharmaceuticals has 156 employees.

What is the current trading status of ImmuneOnco Biopharmaceuticals (1541)?

As of 10 Aug 2025, ImmuneOnco Biopharmaceuticals (1541) is trading at a price of 11.06, with a previous close of 11.06. The stock has fluctuated within a day range of 10.70 to 11.35, while its 52-week range spans from 3.21 to 15.66.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.